ASAPF logo

Aurora Spine Corporation (ASAPF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Aurora Spine Corporation (ASAPF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 48/100

Aurora Spine Corporation (ASAPF) Resumen de Asistencia Médica y Tuberías

CEOTrent J. Northcutt
Sede CentralToronto, CA
Año de la oferta pública inicial (OPI)2013

Aurora Spine Corporation, a Canadian medical device company, specializes in minimally invasive spinal fusion technologies, including interspinous fusion devices and interbody cages, targeting patients with degenerative disc diseases. With a focus on innovation and 3D-printed implants, Aurora Spine operates within the competitive medical device landscape.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Aurora Spine Corporation presents a focused investment opportunity within the medical device sector, specifically targeting the spinal fusion market. The company's emphasis on minimally invasive techniques and innovative products like the SOLO and DEXA-C devices could drive future growth. With a market capitalization of $0.02 billion, Aurora Spine operates with a negative P/E ratio of -11.66 and a negative profit margin of -7.4%, indicating potential for improved profitability. A gross margin of 59.7% suggests efficient production and pricing strategies. Key catalysts include expanding distribution networks and securing regulatory approvals for new products. However, investors should be aware of the risks associated with the OTC market and the company's current financial performance.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.02 billion indicates a small-cap company with potential for growth.
  • Negative P/E ratio of -11.66 reflects current unprofitability, suggesting potential for future earnings improvement.
  • Gross margin of 59.7% demonstrates efficient cost management in product manufacturing and sales.
  • Beta of -0.54 suggests the stock is less volatile than the market, potentially offering stability during market downturns.
  • Focus on minimally invasive spinal fusion technologies positions the company in a growing segment of the medical device market.

Competidores y Pares

Fortalezas

  • Innovative interspinous fusion technology.
  • Focus on minimally invasive solutions.
  • 3D-printing capabilities for customized implants.
  • Established distribution network in Canada.

Debilidades

  • Limited market presence outside of Canada.
  • Negative profitability and reliance on external funding.
  • Small market capitalization and limited resources.
  • Dependence on key product lines.

Catalizadores

  • Upcoming: FDA approval for key products (ZIP, SOLO) for US market entry.
  • Upcoming: Strategic partnerships with hospitals and surgical centers to expand distribution.
  • Ongoing: Increasing adoption of 3D-printed implants in spinal fusion procedures.
  • Ongoing: Development and launch of new spinal fusion technologies.
  • Ongoing: Expansion of sales and marketing efforts in the Canadian market.

Riesgos

  • Potential: Competition from larger medical device companies with greater resources.
  • Potential: Regulatory hurdles and delays in obtaining FDA approvals.
  • Potential: Product liability and litigation risks associated with spinal implants.
  • Ongoing: Negative profitability and reliance on external funding.
  • Ongoing: Limited market presence outside of Canada.

Oportunidades de crecimiento

  • Expansion into the US Market: Aurora Spine has the opportunity to expand its market reach into the United States, a significantly larger market for spinal implants. Securing FDA approval for its key products, such as the ZIP and SOLO systems, would be crucial for this expansion. The US spinal implant market is estimated to be worth billions of dollars annually, offering substantial revenue potential for Aurora Spine. Timeline: 2-3 years for regulatory approvals and market entry.
  • Increased Adoption of 3D-Printed Implants: Aurora Spine's DEXA-C cervical interbody system, which utilizes 3D-printed technology, presents a growth opportunity. As 3D printing becomes more prevalent in medical device manufacturing, Aurora Spine can capitalize on the demand for customized and porous implants that promote bone growth. The 3D-printed medical device market is experiencing rapid growth, driven by its ability to create patient-specific solutions. Timeline: Ongoing, with increasing adoption over the next 5 years.
  • Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with hospitals, surgical centers, and distributors can accelerate Aurora Spine's market penetration. Collaborations with established players in the medical device industry can provide access to wider distribution networks and increased brand visibility. These partnerships can also facilitate the adoption of Aurora Spine's products by surgeons and healthcare providers. Timeline: 1-2 years to establish key partnerships.
  • Development of New Spinal Fusion Technologies: Investing in research and development to create new and innovative spinal fusion technologies can drive future growth. Focusing on areas such as motion preservation, regenerative medicine, and personalized implants can differentiate Aurora Spine from its competitors. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry. Timeline: Ongoing, with new product launches every 2-3 years.
  • Focus on Minimally Invasive Surgical Techniques: The increasing demand for minimally invasive surgical procedures presents a growth opportunity for Aurora Spine. The company's ZIP system and other interspinous fusion devices align with this trend, offering patients less invasive alternatives to traditional spinal fusion. As more surgeons adopt minimally invasive techniques, the demand for Aurora Spine's products is expected to increase. Timeline: Ongoing, with increasing adoption over the next 5 years.

Oportunidades

  • Expansion into the US market.
  • Increased adoption of 3D-printed implants.
  • Strategic partnerships and distribution agreements.
  • Development of new spinal fusion technologies.

Amenazas

  • Competition from larger medical device companies.
  • Regulatory hurdles and approval processes.
  • Product liability and litigation risks.
  • Economic downturns and healthcare spending cuts.

Ventajas competitivas

  • Proprietary interspinous fusion technology (ZIP system).
  • Focus on minimally invasive surgical techniques.
  • 3D-printed implant capabilities (DEXA-C).
  • Established presence in the Canadian market.

Acerca de ASAPF

Aurora Spine Corporation, established in 2013 and headquartered in Toronto, Canada, operates through its subsidiary, Aurora Spine, Inc., focusing on the design, development, and commercialization of minimally invasive spinal implant systems. The company's core business revolves around addressing spinal pathologies through innovative interspinous fusion and interbody technologies. Their product portfolio includes a range of interspinous process lumbar fusion devices like the ZIP family (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51), designed to alleviate pain and stabilize the spine in patients with degenerative disc diseases. These devices offer a less invasive alternative to traditional spinal fusion surgeries. In addition to interspinous devices, Aurora Spine offers Ti-Coated polyether ether ketone (PEEK) interbody cages, which provide structural support and promote bone growth between vertebrae during fusion. The company also provides sterile-packed titanium plasma spray coated spinal infusion implants. Their interbody product line includes EOS, VOX, Echo, Echo SD, and EchoXL for lumbar applications, and Discovery for cervical procedures. Aurora Spine has also introduced SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, and SiLo, a posterior fusion device for the sacroiliac joint. Further expanding their offerings, DEXA-C, a cervical interbody system, utilizes porous 3D-printed intervertebral body fusion devices with customizable lattice patterns to match individual patient bone quality. Aurora Spine primarily serves the Canadian market, focusing on providing advanced spinal solutions to improve patient outcomes and quality of life.

Qué hacen

  • Develops minimally invasive interspinous fusion systems.
  • Distributes spinal implants and devices.
  • Offers interspinous process lumbar fusion devices (ZIP, ZIP ULTRA, ZIP LP, ZIP-51).
  • Provides Ti-Coated polyether ether ketone interbody cages.
  • Manufactures sterile-packed titanium plasma spray coated spinal infusion implants.
  • Offers interbody products (EOS, VOX, Echo, Echo SD, EchoXL, Discovery).
  • Provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device.
  • Offers SiLo, a posterior fusion device for the sacroiliac joint.

Modelo de Negocio

  • Develops and manufactures spinal implants and devices.
  • Sells products directly to hospitals and surgical centers.
  • Utilizes distributors to reach a wider customer base.
  • Generates revenue through the sale of its spinal fusion products.

Contexto de la Industria

Aurora Spine Corporation operates within the medical device industry, specifically focusing on spinal implants and fusion technologies. The global spinal implants and surgery devices market is projected to reach billions of dollars by 2026, driven by an aging population, increasing prevalence of spinal disorders, and advancements in minimally invasive surgical techniques. The competitive landscape includes established players like BTCY, CLCS, EMITF, GTHP, and IMMVF, as well as larger medical device companies. Aurora Spine differentiates itself through its focus on innovative designs, 3D-printed implants, and interspinous fusion devices.

Clientes Clave

  • Hospitals
  • Surgical centers
  • Spinal surgeons
  • Patients suffering from degenerative disc diseases
Confianza de la IA: 69% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Aurora Spine Corporation (ASAPF): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para ASAPF.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ASAPF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para ASAPF.

MoonshotScore

48/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de ASAPF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Trent J. Northcutt

Unknown

Information on Trent J. Northcutt's background is not available in the provided context. Further research would be needed to provide details on his career history, education, and previous roles.

Historial: Information on Trent J. Northcutt's track record is not available in the provided context. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under his leadership.

Información del mercado OTC de ASAPF

The OTC Other tier represents the lowest tier of the OTC market, indicating that Aurora Spine Corporation may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for stocks traded on the OTC Other tier is typically very low, characterized by thin trading volume and wide bid-ask spreads. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The limited liquidity also increases the risk of price manipulation and volatility. Investors should exercise caution and be prepared for potential difficulties in executing trades.
Factores de riesgo OTC:
  • Limited financial disclosure and transparency.
  • Low trading volume and liquidity.
  • Higher risk of price manipulation.
  • Potential for delisting or suspension of trading.
  • Limited regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's intellectual property and patent portfolio.
  • Review the company's legal and regulatory compliance.
  • Monitor trading volume and price volatility.
  • Consult with a financial advisor.
Señales de legitimidad:
  • Company has been in operation since 2013.
  • Focus on developing and distributing medical devices.
  • Presence of a physical headquarters in Toronto, Canada.
  • Product portfolio includes multiple spinal fusion devices.

Lo Que los Inversores Preguntan Sobre Aurora Spine Corporation (ASAPF)

¿Cuáles son los factores clave para evaluar ASAPF?

Aurora Spine Corporation (ASAPF) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Innovative interspinous fusion technology.. Riesgo principal a monitorear: Potential: Competition from larger medical device companies with greater resources.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de ASAPF?

ASAPF actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de ASAPF?

Los precios de ASAPF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre ASAPF?

La cobertura de analistas para ASAPF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en ASAPF?

Las categorías de riesgo para ASAPF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from larger medical device companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de ASAPF?

La relación P/E para ASAPF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está ASAPF sobrevalorada o infravalorada?

Determinar si Aurora Spine Corporation (ASAPF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de ASAPF?

Aurora Spine Corporation (ASAPF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available on CEO's background and track record.
  • OTC market stocks carry higher risk than exchange-listed stocks.
Fuentes de datos

Popular Stocks